TCT-486 Acute Thrombogenicity and Inflammation in Response to a Durable Fluoropolymer Everolimus-Eluting Stent Relative to a Durable BioLinx polymer Zotarolimus-Eluting Stent

Background Clinical data indicate differences in acute thrombosis among different drug-eluting stents (DES), which may relate to properties of DES polymer coatings and stent design. Results X-EES showed a significantly lower percentage of adherent platelets on struts as compared to R-ZES and BMS (2.0 % vs. 9.1 % vs. 37.8 %, respectively, p=0.003) (Figure). [...]inflammatory cell density (positive cells/mm2) was lowest for X-EES as compared with R-ZES and BMS for both neutrophils (40.4 ± 16.5 vs. 471.6 ± 211.7 vs. 768.7 ± 458.6, P= 0.0005) and monocytes (33.4 ± 18.6 vs. 287.4 ± 96.1 vs. 399.4 ± 212.9, P= 0.0001).